NeuroTronik Limited and NeuroTronik, Inc., a Dublin, and Durham, NC-based developer of novel neurostimulation therapy for the enhancement of heart function in the hospital or clinic, raised $23.1m in Series B financing.
The round was led by Boston Scientific Group, with participation from Hatteras Venture Partners, Synergy Life Science Partners, Lord Baltimore Investment Partners, Mountain Group Capital, and Sovereign’s Capital, as well as other financial and industry participants.
The company intends to use the funds to receive CE Mark approval of the NeuroTronik CANS Therapy™ System.
Led by Fred McCoy, CEO and Director, NeuroTronik is developing a novel medical technology for physicians to treat heart failure patients who come to the hospital because of their worsened symptoms.
NeuroTronik CANS Therapy™ is cardiac autonomic nerve stimulation delivered via a NeuroCatheter™, placed temporarily in a vein just above the heart, in combination with a NeuroModulator™, positioned bedside.